Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. | Cancer Res;80(10): 2072, 2020 May 15. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.

Li, Shangze; Fong, Ka-Wing; Gritsina, Galina; Zhang, Ali; Zhao, Jonathan C; Kim, Jung; Sharp, Adam; Yuan, Wei; Aversa, Caterina; Yang, Ximing J; Nelson, Peter S; Feng, Felix Y; Chinnaiyan, Arul M; de Bono, Johann S; Morrissey, Colm; Rettig, Matthew B; Yu, Jindan.

Cancer Res ; 80(10): 2072, 2020 May 15.

Article in En | MEDLINE | ID: mdl-32414837

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancer Res Year: 2020 Document type: Article Country of publication: United States

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancer Res Year: 2020 Document type: Article Country of publication: United States